White matter hyperintensities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer's disease.
Alzheimer’s disease
Frontotemporal lobar degeneration
Magnetic resonance imaging
Neuropathology
Neuropsychiatric symptoms
White matter hyperintensity
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
13 07 2021
13 07 2021
Historique:
received:
02
12
2020
accepted:
23
06
2021
entrez:
14
7
2021
pubmed:
15
7
2021
medline:
14
8
2021
Statut:
epublish
Résumé
We aimed to systematically describe the burden and distribution of white matter hyperintensities (WMH) and investigate correlations with neuropsychiatric symptoms in pathologically proven Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD). Autopsy-confirmed cases were identified from the Sunnybrook Dementia Study, including 15 cases of AD and 58 cases of FTLD (22 FTLD-TDP cases; 10 FTLD-Tau [Pick's] cases; 11 FTLD-Tau Corticobasal Degeneration cases; and 15 FTLD-Tau Progressive Supranuclear Palsy cases). Healthy matched controls (n = 35) were included for comparison purposes. Data analyses included ANCOVA to compare the burden of WMH on antemortem brain MRI between groups, adjusted linear regression models to identify associations between WMH burden and neuropsychiatric symptoms, and image-guided pathology review of selected areas of WMH from each pathologic group. Burden and regional distribution of WMH differed significantly between neuropathological groups (F These findings suggest that WMH are associated with neuropsychiatric manifestations in AD and FTLD and that WMH burden and regional distribution in neurodegenerative disorders differ according to the underlying neuropathological processes.
Sections du résumé
BACKGROUND
We aimed to systematically describe the burden and distribution of white matter hyperintensities (WMH) and investigate correlations with neuropsychiatric symptoms in pathologically proven Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD).
METHODS
Autopsy-confirmed cases were identified from the Sunnybrook Dementia Study, including 15 cases of AD and 58 cases of FTLD (22 FTLD-TDP cases; 10 FTLD-Tau [Pick's] cases; 11 FTLD-Tau Corticobasal Degeneration cases; and 15 FTLD-Tau Progressive Supranuclear Palsy cases). Healthy matched controls (n = 35) were included for comparison purposes. Data analyses included ANCOVA to compare the burden of WMH on antemortem brain MRI between groups, adjusted linear regression models to identify associations between WMH burden and neuropsychiatric symptoms, and image-guided pathology review of selected areas of WMH from each pathologic group.
RESULTS
Burden and regional distribution of WMH differed significantly between neuropathological groups (F
CONCLUSIONS
These findings suggest that WMH are associated with neuropsychiatric manifestations in AD and FTLD and that WMH burden and regional distribution in neurodegenerative disorders differ according to the underlying neuropathological processes.
Identifiants
pubmed: 34256835
doi: 10.1186/s13195-021-00869-6
pii: 10.1186/s13195-021-00869-6
pmc: PMC8278704
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
129Subventions
Organisme : CIHR
ID : MOP327387
Pays : Canada
Organisme : CIHR
ID : MOP13129
Pays : Canada
Informations de copyright
© 2021. The Author(s).
Références
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Neuropathol Appl Neurobiol. 2019 Feb;45(1):19-40
pubmed: 30357887
Neuroradiology. 2007 Nov;49(11):905-12
pubmed: 17632713
Arch Neurol. 2006 Jan;63(1):81-6
pubmed: 16401739
Neuroimage. 2011 Jan 15;54(2):963-73
pubmed: 20849961
JAMA Neurol. 2014 Dec;71(12):1562-6
pubmed: 25317628
Brain. 2006 Nov;129(Pt 11):3115-23
pubmed: 17030534
Acta Neuropathol. 2006 Oct;112(4):389-404
pubmed: 16906426
Neurology. 1997 May;48(5 Suppl 6):S10-6
pubmed: 9153155
Neurobiol Aging. 2013 Jul;34(7):1913-20
pubmed: 23414669
Neurology. 2002 Jan 22;58(2):198-208
pubmed: 11805245
Arch Neurol. 2012 Dec;69(12):1583-90
pubmed: 22964832
Brain. 2003 Sep;126(Pt 9):1955-67
pubmed: 12821520
Neurology. 2011 Apr 26;76(17):1492-9
pubmed: 21518999
NPJ Genom Med. 2016 Sep 21;1:16032
pubmed: 29263818
Alzheimers Dement. 2017 Jul;13(7):749-760
pubmed: 28137552
Neurology. 2021 Mar 30;96(13):e1743-e1754
pubmed: 33597290
Alzheimers Res Ther. 2014 Aug 11;6(4):49
pubmed: 25478020
Brain Pathol. 2008 Oct;18(4):484-96
pubmed: 18371174
Stroke. 2006 Sep;37(9):2220-41
pubmed: 16917086
Neurology. 2010 Dec 14;75(24):2204-11
pubmed: 21172843
Acta Neuropathol Commun. 2015 Sep 30;3:60
pubmed: 26419828
Alzheimers Res Ther. 2014 Dec 05;6(9):71
pubmed: 25484929
Neurology. 2006 Jan 10;66(1):23-9
pubmed: 16401840
J Alzheimers Dis. 2018;63(4):1347-1360
pubmed: 29843242
Acta Neuropathol. 2007 Jul;114(1):5-22
pubmed: 17579875
Neuroimage Clin. 2017 Apr 26;15:171-180
pubmed: 28529873
Stroke. 1995 Jul;26(7):1171-7
pubmed: 7604409
Acta Neuropathol. 2009 Jan;117(1):15-8
pubmed: 19015862
J Alzheimers Dis. 2017;60(3):1161-1170
pubmed: 28984590
Acta Neuropathol. 2011 Jul;122(1):111-3
pubmed: 21644037
J Neuropsychiatry Clin Neurosci. 2009 Summer;21(3):259-65
pubmed: 19776304
J Neuropathol Exp Neurol. 2017 Apr 1;76(4):299-312
pubmed: 28431180
Brain. 2005 Jun;128(Pt 6):1259-66
pubmed: 15843423
J Neuroinflammation. 2007 Feb 11;4:7
pubmed: 17291356
Dement Geriatr Cogn Disord. 1998 Jul;9 Suppl 1:6-12
pubmed: 9716238
Alzheimers Dement. 2012 Jan;8(1):1-13
pubmed: 22265587
Acta Neuropathol. 2012 Jan;123(1):1-11
pubmed: 22101365
Neurology. 2017 Sep 19;89(12):1256-1264
pubmed: 28855404
Neurology. 2004 Feb 24;62(4):591-600
pubmed: 14981176